Special Issue

Pharmacogenomics of Oncology Therapies

Message from the Guest Editor

Background: Precision medicine in the form of pharmacogenomics (PGx) is an ever-increasing area of practice in the oncology care setting. Many examples exists as to how genetic polymorphisms influence a drug's effect by altering its PK-PD. However for cancer therapies, which are often limited by a narrow therapeutic index and inter-individual variation in response, a better understanding of how genetic factors influence drug metabolism/transport and consequent treatment outcomes is still critically needed. Aim and Scope: The aim of this Special Issue is to provide recent trends, updates, and progress on how PGx, on both the basic science and clinical level, is improving cancer care. What kind of papers we are soliciting: We are inviting the submission of original articles to this Special Issue of JPM that covers the whole spectrum of PGx of oncology therapies and adjuvant drugs used in the cancer care setting – from basic science to case reports and full clinical studies, and relevant review articles.

Guest Editor

Dr. Alan L. Myers

Department of Diagnostic and Biomedical Sciences, University of Texas Health Science Center Houston, Houston, TX, USA

Deadline for manuscript submissions

closed (1 November 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/42959

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

